NeoImmuneTech, Inc. (KOSDAQ:950220)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,505.00
-325.00 (-11.48%)
May 18, 2026, 7:45 AM KST
Market Cap247.66B -56.1%
Revenue (ttm)94.82M -44.3%
Net Income-31.80B
EPS-270.20
Shares Out98.87M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,948,941
Average Volume909,472
Open2,700.00
Previous Close2,830.00
Day's Range2,320.00 - 2,705.00
52-Week Range1,835.00 - 9,405.00
Betan/a
RSI51.78
Earnings DateMay 21, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 950220
Full Company Profile

Financial Performance

In 2025, NeoImmuneTech's revenue was 94.82 million, a decrease of -44.35% compared to the previous year's 170.38 million. Losses were -31.80 billion, -22.23% less than in 2024.

Financial Statements